Treprostinil sodium
ApprovedSmall molecule
United TherapeuticsTreprostinil sodium is one of 72 small molecule programs targeting Liver Transplant. It is currently in Approved.
3
Indications
6
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
353 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Treprostinil sodium
United TherapeuticsApproved
Cysteine Hydrochloride
NovartisPreclinical
Vemlidy
GileadPreclinical
Lenvima
EisaiPreclinical
Octreotide
Johnson & JohnsonPreclinical
Myfortic
NovartisPreclinical
Myfortic
NovartisPreclinical
Cyklokapron
AAmring
Preclinical
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Satisfaction2 trials
Liver Transplant1 trial
Pulmonary Arterial Hypertension1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Treprostinil sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company